# Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema

> **NCT00576459** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 40 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** 0.59 mg fluocinolone acetonide intravitreal implant
- **DRUG:** 2.1 mg fluocinolone acetonide intravitreal implant
- **PROCEDURE:** standard of care laser photocoagulation

## Key facts

- **NCT ID:** NCT00576459
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2006-06
- **Final completion:** 2006-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2011-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576459, "Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00576459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*